Orthopedic Surgeons Highlight Gaps in Preoperative Bone Density Evaluation Prior to Arthroplasty

Key facts

The report published by Becker's Spine Review focused on the contrast between rigorous general preoperative clearance and the frequent omission of metabolic bone assessment in joint reconstruction practices. In modern elective total joint arthroplasty—which includes total hip, knee, and shoulder replacements—patients undergo extensive medical workups to ensure surgical safety. Practitioners routinely order electrocardiograms, laboratory blood counts, hemoglobin A1c assessments, and nutritional panels to minimize acute perioperative risks.

However, the report emphasized that assessment of the underlying bony architecture into which joint prostheses are anchored is regularly overlooked. Becker's Spine Review quoted an unnamed medical practitioner who pointed out that orthopedic surgeons are generally not accustomed to treating chronic medical conditions over extended periods using long-term medication protocols. This cultural and training gap within surgical subspecialties has led to situations where patients with undiagnosed osteopenia or osteoporosis undergo elective joint replacement without prior medical optimization of their skeleton.

The analysis characterized this oversight as a major pre-operative blind spot. When surgeons insert non-cemented prostheses into porous or brittle bone without prior medical enhancement, the immediate mechanical stability and long-term biological integration of the implant can be severely compromised. According to the commentary highlighted by Becker's Spine Review, addressing bone health prior to surgical intervention should become a standard pillar of preoperative preparation, with failure to do so increasingly viewed as unacceptable in modern orthopedic practice.

Why it matters

The mechanical success of total joint arthroplasty depends fundamentally on the structural integrity of the host bone surrounding the implant. In primary total hip and knee arthroplasties, modern surgical techniques frequently rely on uncemented press-fit components. These devices require the host bone to undergo biological osseointegration, wherein microscopic bone tissue grows directly into the porous surface of the titanium or cobalt-chromium implant. When a patient suffers from underlying osteoporosis or osteopenia, this biological inward growth is impaired, leaving the implant vulnerable to micromotion, pain, and early mechanical failure.

Furthermore, compromised bone density substantially increases the risk of periprosthetic fractures—fractures occurring around the metallic implants—either during surgical insertion or in the early postoperative recovery period. Treating a periprosthetic fracture typically requires major revision surgery, complex internal fixation, longer hospital stays, and elevated rates of post-surgical complications and mortality.

From a financial and health systems perspective, revision joint replacements cost significantly more than primary joint replacements, placing a heavy burden on commercial insurers, Medicare, and public healthcare budgets. By identifying metabolic bone fragility before entering the operating room, surgical teams can initiate bone-building therapies or modify surgical techniques—such as utilizing cemented fixation rather than press-fit components—thereby avoiding catastrophic mechanical failures and costly revision operations.

Total joint arthroplasty has evolved over the past half-century into one of the most successful and frequent surgical interventions in global healthcare. In established clinical context, hundreds of thousands of total hip and knee replacements are performed each year in North America and Europe to relieve debilitating osteoarthritis and restore patient mobility.

Historically, joint replacements relied primarily on polymethylmethacrylate bone cement to anchor implants directly to host bone. While cemented fixation provided immediate mechanical stability, long-term concerns over cement breakdown and loosening led to the widespread development and adoption of uncemented, press-fit prostheses in the 1980s and 1990s. Press-fit implants require sturdy, healthy trabecular bone to achieve primary stability and subsequent osseointegration.

Diagnostic evaluation of bone health relies on dual-energy X-ray absorptiometry scans, commonly known as DEXA scans. DEXA scanning measures bone mineral density, expressing results as a T-score that compares a patient's bone mass to that of a healthy young adult reference population. In standard diagnostic classification established by the World Health Organization, a T-score between -1.0 and -2.5 indicates osteopenia (low bone mass), while a T-score of -2.5 or lower signifies osteoporosis.

Pharmacological treatments for bone fragility fall into two major categories: antiresorptive agents and anabolic agents. Antiresorptive medications, including bisphosphonates such as alendronate and zoledronic acid, as well as RANK-ligand inhibitors like denosumab, slow down the breakdown of existing bone tissue. Anabolic agents, including teriparatide, abaloparatide, and romosozumab, actively stimulate new bone formation. In non-emergent elective arthroplasty, administering bone-building agents for three to twelve months prior to surgery can significantly increase local bone mineral density, improving implant stability. Despite these medical options, formal preoperative bone management protocols remain inconsistently adopted across orthopedic practices.

Reaction

Professional orthopedic societies and clinical subspecialists have increasingly recognized the necessity of bridging the gap between surgical orthopedics and metabolic bone medicine. Organizations such as the American Orthopaedic Association have championed bone health initiatives, including the "Own the Bone" quality improvement program, which encourages hospitals and clinics to establish secondary fracture prevention and bone health screening pathways.

While the brief commentary published by Becker's Spine Review did not outline immediate formal responses from medical associations, industry analysts expect increased pressure on professional bodies—such as the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons—to establish standardized preoperative bone screening guidelines.

Endocrinologists and rheumatologists have supported multidisciplinary co-management models, arguing that orthopedic surgeons should collaborate closely with bone specialists when fragile bone is detected prior to elective procedures. Conversely, surgical administrators have raised logistical concerns regarding potential delays in elective surgery schedules, as pre-op metabolic bone optimization can delay surgical intervention by several months while medical therapies take effect.

What we don't know yet

Several specific details surrounding the commentary reported by Becker's Spine Review remain unverified due to the brevity of the published summary text:

What to watch

In the coming months and years, key indicators will determine whether preoperative bone health screening becomes standard practice across the orthopedic discipline:

This article is based on reporting published by Becker's Spine Review on Sept. 2, 2026.